What’s new

• BSE in-principle approval for 2.125 cr convertible warrants and 56.5 lakh equity shares at ₹10 each.
• Proceeds exceed half the company's market capitalisation of ~₹57 cr.
• Prior proposal was much smaller; significant escalation in scale.

Why it matters

For a nano-cap with negative net worth and no revenue, a ₹26.9 cr infusion equals half its market cap. The money can wipe out negative equity and fund working capital, but the dilution is massive — nearly doubling the share count if all warrants convert.

What we’re watching

• Whether the 15-day approval window is met and funds are raised.
• Conversion and usage of proceeds to reduce negative net worth.
• Any follow-on equity offerings or turnaround in revenue.

The full read

Callista Industries has BSE in-principle approval to raise ₹26.9 crore via a preferential issue, 48% of its ₹57 crore market cap. The issue includes 2.12 crore convertible warrants and 56.5 lakh shares at ₹10 each. For a nano-cap with negative net worth and zero revenue, this infusion is existential. It can wipe out negative equity and provide working capital, but the dilution is extreme: if all warrants convert, the share count doubles. The 15-day approval window adds urgency. This is a high-stakes bet on turnaround, riding entirely on promoter conviction and market appetite.

Primary source: BSE · NSE